Connect
Each year, more than 288,000 men in the U.S. are diagnosed with prostate cancer. By 2040, this number could double. Researchers at Mayo Clinic have discovered a promising way to treat prostate cancer by targeting a specific genetic mutation in cancer cells. This breakthrough could lead to better treatments for patients with advanced prostate cancer.
How the SPOP Mutation Affects Cancer Cells
A mutation in the SPOP (Speckle-type POZ protein) gene causes cancer cells to copy their DNA incorrectly. The ATR (Ataxia Telangiectasia and Rad3-related) protein helps fix these errors, allowing cancer cells to survive. A drug called an ATR inhibitor can block this process, making it harder for cancer cells to grow.
Key Findings
In lab studies, researchers tested an ATR inhibitor called VE-822 on cancer cells with the SPOP mutation. The drug slowed tumor growth and killed cancer cells, proving it could take advantage of this genetic weakness.
Next Steps
These findings have led to a Phase II clinical trial of another ATR inhibitor, tuvesertib, for patients with SPOP-mutated prostate cancer. If successful, this research could lead to a new treatment option.
Community Impact
This study shows that targeting specific genetic weaknesses in cancer cells may lead to better treatments for prostate cancer —especially for patients whose cancer resists traditional therapies.
Researchers: J. Orme, M.D., Ph.D., and H. Huang, Ph.D.
Get Involved
You can help shape the future of health research by getting involved in Mayo Clinic’s community-integrated research. Click here to learn how to raise your voice, use your lived experience, or represent your community to help improve health for everyone.
Like
Helpful
Hug
Connect